Get started
Author

Shuyi Ding

Observed names: Shu-Yi Ding, Shuyi DING
OpenAlex ID: A5032106938
New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
2021 · Linqin Wang, Ruimin Hong, et al. · Frontiers in Oncology · 48
PDF
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
2023 · Weijia Wu, Shuyi Ding, et al. · Journal of Medical Economics · 20
PDF
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies
2024 · Linqin Wang, Yuqi Lv, et al. · Experimental Hematology and Oncology · 13
PDF
Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study
2022 · Shuyi Ding, Lingxia Cai, et al. · Supportive Care in Cancer · 11
PDF
Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor–T-cell therapy
2022 · Linqin Wang, Ruimin Hong, et al. · Cytotherapy · 9
Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
2023 · Shuyi Ding, Rongrong Chen, et al. · BMC Cancer · 6
PDF
Symptom clusters and sentinel symptoms during post-transplant recovery in recipients of allogeneic hematopoietic stem cell transplantation: A cross-sectional study
2025 · Ping Xu, Shuyi Ding, et al. · Asia-Pacific Journal of Oncology Nursing · 4
Psychological and physical side effects during G-CSF mobilization in related donors of allo-HCT
2024 · Lingxia Cai, Diange Jin, et al. · Annals of Hematology · 3
Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
2022 · Linghui Zhou, Elaine Tan Su Yin, et al. · ImmunoMedicine · 3
PDF
Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization
2025 · Mengqi Yu, Tingting Yang, et al. · American Journal of Hematology · 2
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor ( CAR)‐T cell therapy in patients with hematological malignancy
2023 · Liu Chen, Shuyi Ding, et al. · European Journal Of Haematology · 2
Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
2022 · Yuqi LYU, Mingming ZHANG, et al. · Journal of Zhejiang University (Medical Sciences) · 2
Development and implementation of evidence-based, nurse-leading early warning model and healthcare quality improvement project for transplant-associated thrombotic microangiopathy: a mixed-methods, before-and-after study
2024 · Xiaoyu Zhou, Yishan Ye, et al. · BMC Nursing · 1
PDF
Cost Effectiveness Analysis of CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma in China
2022 · Weijia Wu, Shuyi Ding, et al. · Research Square · 1
PDF
Compound staphylococcal lysostaphin for oral mucositis prophylaxis in hematopoietic stem cell transplantation recipients: a non-inferiority randomized trial
2025 · Xiaoyu Zhou, Zhengwen Pan, et al. · British Journal of Cancer
Risk factors for non-infectious diarrhea of patients with multiple myeloma after chimeric antigen receptor T- cell immunotherapy: A retrospective observational study
2023 · Shu-Yi Ding, Yin Cheng, et al. · Research Square
PDF
Instruments on symptom clusters in adult patients with hematological malignancies: A scoping review
2023 · Yin Cheng, Jiali Yan, et al. · Research Square
PDF
Title: Risk factors for non-infectious diarrhea of patients with multiple myeloma after chimeric antigen receptor T-cell immunotherapy: A retrospective observational study
2023 · Shu-Yi Ding, Yin Cheng, et al. · Research Square
PDF
Works count: 18
Citation count: 125
H-index: 6
I10-index: 4
Year
Topic
Type